Skip to contentP
Perspective Therapeutics, Inc.
P
CATXPerspective Therapeutics, Inc. Q1 2019 · 10-Q
Revenue$1.56M$1.56M+29.0% vs Q1 2018 Net Income-$1.51M-$1.51MN/M vs Q1 2018 EPS Diluted-$0.02-$0.02N/M vs Q1 2018 Gross Profit$524,000+97.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Perspective Therapeutics, Inc. · CIK 728387 · Engraved from SEC EDGAR
Operating Cash Flow-$1,612,000N/M Free Cash Flowderived-$1,726,000N/M Margins · derivedGross margin33.5%+11.7 pt vs Q1 2018
Operating margin-97.2%+31.0 pt vs Q1 2018
Net margin-96.5%+31.1 pt vs Q1 2018
ended Sep 30, 2018 · filed Nov 9, 2018 · 40 d after period end